We then investigated in vivo whether inhibition of both receptor signalling pathways with a combination of Irbesartan (Irb; AT1 receptor antagonist) and Propagermanium (PPG; CCR2 pathway inhibitor) could potentially have a synergistic benefit for CKD treatment, which would be consistent with functional interaction of these receptor signalling pathways. Here, AGTR1 is linked to chronic kidney disease.